ArTS Archivio della ricerca di Trieste

GENERALI, DANIELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 16.981
EU - Europa 8.862
AS - Asia 2.855
SA - Sud America 39
AF - Africa 38
OC - Oceania 20
Continente sconosciuto - Info sul continente non disponibili 4
Totale 28.799
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 16.942
PL - Polonia 4.583
IT - Italia 1.191
SE - Svezia 1.122
SG - Singapore 796
CN - Cina 765
HK - Hong Kong 657
UA - Ucraina 437
DE - Germania 371
TR - Turchia 318
BG - Bulgaria 256
IE - Irlanda 255
FI - Finlandia 227
VN - Vietnam 115
GB - Regno Unito 87
RU - Federazione Russa 67
ES - Italia 51
IN - India 48
BE - Belgio 45
FR - Francia 43
MY - Malesia 37
BR - Brasile 27
CA - Canada 26
RO - Romania 23
JP - Giappone 22
NL - Olanda 22
IL - Israele 19
KR - Corea 19
AU - Australia 18
CH - Svizzera 16
SN - Senegal 12
TH - Thailandia 11
MX - Messico 10
AT - Austria 9
CZ - Repubblica Ceca 9
EE - Estonia 9
DK - Danimarca 8
IR - Iran 8
TW - Taiwan 8
EG - Egitto 7
CL - Cile 6
SA - Arabia Saudita 6
ZA - Sudafrica 6
GR - Grecia 5
JO - Giordania 5
MD - Moldavia 5
RS - Serbia 5
A2 - ???statistics.table.value.countryCode.A2??? 4
AM - Armenia 4
DZ - Algeria 4
HU - Ungheria 4
PK - Pakistan 4
CI - Costa d'Avorio 3
HR - Croazia 3
PT - Portogallo 3
SC - Seychelles 3
AR - Argentina 2
BO - Bolivia 2
DO - Repubblica Dominicana 2
NZ - Nuova Zelanda 2
OM - Oman 2
SK - Slovacchia (Repubblica Slovacca) 2
SY - Repubblica araba siriana 2
TN - Tunisia 2
AE - Emirati Arabi Uniti 1
AZ - Azerbaigian 1
BN - Brunei Darussalam 1
CR - Costa Rica 1
EC - Ecuador 1
GE - Georgia 1
ID - Indonesia 1
IQ - Iraq 1
LA - Repubblica Popolare Democratica del Laos 1
LT - Lituania 1
LU - Lussemburgo 1
LV - Lettonia 1
MA - Marocco 1
NP - Nepal 1
PE - Perù 1
PH - Filippine 1
SI - Slovenia 1
Totale 28.799
Salva come PNG Salva come JPEG
Città #
Warsaw 4.572
Fairfield 2.597
Woodbridge 1.988
Houston 1.591
Ashburn 1.348
Ann Arbor 1.333
Chandler 1.115
Wilmington 1.096
Seattle 1.072
Cambridge 951
Singapore 666
Hong Kong 646
Jacksonville 597
Princeton 470
Trieste 395
Izmir 306
Dublin 255
Sofia 255
Beijing 237
Santa Clara 157
Boardman 152
San Diego 126
Dong Ket 108
Dearborn 68
Falls Church 62
Helsinki 57
Milan 52
Bremen 51
Columbus 44
Redwood City 39
Norwalk 38
Brussels 37
Dongguan 36
Phoenix 35
Kerken 34
Chicago 30
Duino-Aurisina 30
Rome 28
Dallas 26
Redmond 26
New York 24
Hefei 23
Venice 22
Buffalo 21
Fremont 21
Nanjing 21
Des Moines 20
Jinan 20
Shanghai 20
São Paulo 19
Barcelona 18
London 18
Udine 18
Los Angeles 17
Padova 17
Pignone 17
Tel Aviv 17
Kunming 16
Lappeenranta 16
San Antonio 16
Amsterdam 15
Tappahannock 15
Toronto 15
Guangzhou 14
Madrid 14
Dottingen 13
Hangzhou 13
Tokyo 13
Boydton 12
Dakar 12
Florence 12
Horia 12
Seoul 12
Montegaldella 11
Shenyang 11
Turin 11
Edinburgh 10
Nanchang 10
San Francisco 10
Zhengzhou 10
Bangkok 9
Fuzhou 9
Paris 9
Schoenwalde 9
Toenisvorst 9
Pune 8
Vienna 8
Indiana 7
Tianjin 7
Venezia 7
Council Bluffs 6
Frankfurt am Main 6
Freiburg im Breisgau 6
Grafing 6
Renton 6
Rho 6
Treviso 6
Turku 6
Baltimore 5
Bari 5
Totale 23.492
Salva come PNG Salva come JPEG
Nome #
Whole-transcriptome analysis links trastuzumab sensitivity of breast tumors to both HER2 dependence and immune cell infiltration 371
Cyclin dependent kinase 4 and 6 inhibitors as novel therapeutic agents for targeted treatment of malignant mesothelioma 369
Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer 348
Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial 326
Efficacy and safety of T-DM1 in the 'common-practice' of HER2+ advanced breast cancer setting: a multicenter study 321
Advances in systemic therapy for metastatic breast cancer: future perspectives 313
Cell-free DNA integrity for the monitoring of breast cancer: Future perspectives? 312
PIK3CA mutation in gastric cancer and the role of microsatellite instability status in mutations of exons 9 and 20 of the PIK3CA gene 312
Enteric-coated and highly standardized cranberry extract reduces antibiotic and nonsteroidal anti-inflammatory drug use for urinary tract infections during radiotherapy for prostate carcinoma 311
Current challenges in HER2-positive breast cancer 308
Designing a broad-spectrum integrative approach for cancer prevention and treatment 305
Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition 300
Isolated testicular metastasis from prostate cancer 290
Characterization of MTAP gene expression in breast cancer patients and cell lines 289
Circulating tumor cells correlate with patterns of recurrence in patients with hormone-sensitive prostate cancer 289
Tumor-infiltrating lymphocytes and breast cancer: Beyond the prognostic and predictive utility 281
Would the combination of everolimus with endocrine-therapy help in FGFR2 positive serous endometrial cancer? 279
Bevacizumab in small cell lung cancer 277
NEODUCTGENESIS AS A PROGNOSTIC MARKER IN “DUCTAL” CARCINOMA IN SITU OF THE BREAST 274
Broad targeting of angiogenesis for cancer prevention and therapy 273
Hypoxia-related biological markers as predictors of epirubicinbased treatment responsiveness and resistance in locally advanced breast cancer 271
Triple Negative Breast Cancers Have a Reduced Expression of DNA Repair Genes 266
Association between ramucirumab-related hypertension and response to treatment in patients with metastatic gastric cancer 256
Current status of PI3K-mTOR inhibition in hormone-receptor positive, HER2-negative breast cancer 253
Need for randomized clinical trials testing targeted therapies in malignant pleural mesothelioma 247
Platinum sensitivity and DNA repair in a recently established panel of patient-derived ovarian carcinoma xenografts 244
Targeting the androgenic pathway in elderly patients with castration-resistant prostate cancer: A meta-analysis of randomized trials 240
Tumour infiltrating lymphocytes and immune-related genes as predictors of outcome in pancreatic adenocarcinoma 239
The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells 234
Early immune modulation by single-agent trastuzumab as a marker of trastuzumab benefit 234
PAK6-Associated Support Vector Machine Classifier: A New Way to Evaluate Response and Survival of Gastric Cancer Treated by 5-FU/Oxaliplatin Chemotherapy 232
Cell-free DNA analysis in healthy individuals by next-generation sequencing: a proof of concept and technical validation study. 227
Inhibitors of Tumor Angiogenesis 219
A network meta-analysis of everolimus plus exemestane versus chemotherapy in the first- and second-line treatment of estrogen receptor-positive metastatic breast cancer 204
Abemaciclib: A CDK4/6 inhibitor for the treatment of HR+/HEeR2- advanced breast cancer 202
Tumour infiltrating lymphocytes and PD-L1 expression as potential predictors of outcome in patients with malignant pleural mesothelioma 200
Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study 185
Correction: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study 174
Advances in systemic therapy for malignant mesothelioma: Future perspectives 171
COX-2 expression is predictive for early relapse and aromatase inhibitor resistance in patients with ductal carcinoma in situ of the breast, and is a target for treatment 165
The prognostic value of PI3K mutational status in breast cancer: A meta-analysis 165
The G-protein-coupled receptor CLR is upregulated in an autocrine loop with adrenomedullin in clear cell renal cell carcinoma and associated with poor prognosis 164
Low-Dose Oral Ethinylestradiol With Concomitant Low-Dose Acetylsalicylic Acid for Advanced Castrate-Resistant Prostate Cancer 162
Benefit of the addition of hormone therapy to neoadjuvant anthracycline-based chemotherapy for breast cancer: comparison of predicted and observed pCR 160
PROGNOSTIC ROLE OF TUMOR INFILTRATING LYMPHOCITES (TILS) IN EPITHELIOID PLEURAL MESOTHELIOMA 158
Management of the axilla in breast cancer: outcome analysis in a series of ductal versus lobular invasive cancers 158
CDK4/6 inhibitors in HER2-positive breast cancer 157
Clinical validity of circulating tumour cells in patients with metastatic breast cancer: A pooled analysis of individual patient data 152
The relevance of chemobrain in breast cancer survivors: An Italian exploratory study to measure incidence and psycho-social impact 152
Low dose versus standard dose of corticosteroids in the management of adverse events of special interest from abiraterone acetate: data from a literature-based meta-analysis 151
Apatinib for the treatment of gastric cancer 143
Are EGFR tyrosine kinase inhibitors effective in elderly patients with EGFR-mutated non-small cell lung cancer? 143
RNA disruption and drug response in breast cancer primary systemic therapy 142
International expert consensus on primary systemic therapy in the management of early breast cancer: Highlights of the Fifth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2013) 142
Practice patterns regarding drains management in breast surgery: Results of a survey of Senonetwork Italia breast centers 141
Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer 139
null 137
Predictive immunohistochemical biomarkers in the context of neoadjuvant therapy for breast cancer 137
Apatinib: A novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer 135
Prospective neoadjuvant analysis of PET imaging and mechanisms of resistance to Trastuzumab shows role of HIF1 and autophagy 133
Neoadjuvant treatment approach: The rosetta stone for breast cancer? 133
Different efficacy of ramucirumab in patients with metastatic gastric and gastroesophageal junction cancer according to ECOG performance status 133
Ibrutinib: from bench side to clinical implications 133
Circulating tumor cells in breast cancer patients treated by neoadjuvant chemotherapy: A Meta-analysis 132
Pertuzumab therapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer 132
High-dose chemotherapy with autologous hematopoietic stem cell transplantation for high-risk primary breast cancer 132
Gene expression profiling in breast cancer: A clinical perspective 131
Current status of androgen receptor-splice variant 7 inhibitor niclosamide in castrate-resistant prostate-cancer 130
Lenvatinib for the treatment of renal cell carcinoma 129
The role of bevacizumab in solid tumours: A literature based meta-analysis of randomised trials 128
A Phase Ib Open-Label Study to Assess the Safety and Tolerability of Everolimus in Combination with Eribulin in Triple-Negative Breast Cancers 126
Risk of hypertension with ramucirumab-based therapy in solid tumors: data from a literature based meta-analysis 126
Could gonadotropin-releasing hormone analogs be helpful in the treatment of triple-negative breast cancer? 125
Positron emission tomography and neoadjuvant therapy of breast cancer 125
New omics information for clinical trial utility in the primary setting 124
Is the fatigue an adverse event of the second generation of hormonal therapy? Data from a literature-based meta-analysis 123
Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer 122
Variations along the 24-hour cycle of circulating osteoprotegerin and soluble RANKL: A rhythmometric analysis 122
Colorectal cancer-screening program improves both short- and long-term outcomes: a single-center experience in Trieste 121
Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines 120
Everolimus Plus Exemestane in Advanced Breast Cancer: Safety Results of the BALLET Study on Patients Previously Treated Without and with Chemotherapy in the Metastatic Setting 120
Curcumin as an adjunct therapy and microRNA modulator in breast cancer 120
Role of carbonic anhydrase IX expression in prediction of the efficacy and outcome of primary epirubicin/tamoxifen therapy for breast cancer 120
Biological therapies for metastatic breast cancer: Antiangiogenesis 119
Lower urinary tract infections from external beam radiation therapy in prostate cancer: A single institution experience 119
Comparison of molecular subtyping with BluePrint, MammaPrint, and TargetPrint to local clinical subtyping in breast cancer patients 118
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for treatment of ovarian cancer 118
International expert consensus on primary systemic therapy in the management of early breast cancer: Highlights of the fourth symposium on primary systemic therapy in the management of operable breast cancer, Cremona, Italy (2010) 117
Could the long-term persistence of low serum calcium levels and high serum parathyroid hormone levels during bisphosphonate treatment predispose metastatic breast cancer patients to undergo osteonecrosis of the jaw?[5] 115
Targeting fibroblast growth factor receptor in breast cancer: A promise or a pitfall? 115
"Overcoming breast cancer drug resistance with mTOR inhibitors". Could it be a myth or a real possibility in the short-term future? 115
Familial aggregation of gastric cancer with microsatellite instability** 114
Intermediate endpoints of primary systemic therapy in breast cancer patients 114
Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: Results of the randomized phase II CHER-LOB study 113
Erratum to: Advances in systemic therapy for metastatic breast cancer: future perspectives (Medical Oncology, (2017), 34, 7, (119), 10.1007/s12032-017-0975-5) 113
Is there a place for bevacizumab in patients with extensive-stage small cell lung cancer? 112
Anti-Angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients 112
null 112
Breast cancer circulating biomarkers: advantages, drawbacks, and new insights 112
Ado-trastuzumab emtansine (T-DM1) in HER2+ advanced breast cancer patients: does pretreatment with pertuzumab matter? 112
Totale 18.439
Salva come PNG Salva come JPEG
Categoria #
all - tutte 80.449
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 80.449
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20206.317 0 0 404 1.130 556 852 658 531 662 489 617 418
2020/20214.700 467 442 378 530 564 389 437 351 254 349 183 356
2021/20222.792 162 409 197 173 38 192 134 107 379 378 172 451
2022/20233.518 334 361 293 433 366 651 54 313 427 39 175 72
2023/20242.817 119 364 163 188 162 226 476 588 24 122 216 169
2024/20251.217 96 524 597 0 0 0 0 0 0 0 0 0
Totale 29.749